Replies to post #4878 on Pfizer Inc (PFE)

[DewDiligence]

PFE—FDA approves Zavzpret—(zavegepant)—nasal spray for acute migraine:

https://www.businesswire.com/news/home/20230309005795/en

Zavzpret is the “other” asset PFE obtained in the $11.6B buyout of BHVN in 2022 (#msg-168806558).

Between Nurtec and Zavzpret, PFE projects $6B in peak annual sales for the migraine franchise, according to PFE’s Investor Day in Dec 2022 (https://investors.pfizer.com/files/doc_presentation/2022/12/B/Pfizer-Near-Term-Launches-High-Value-Pipeline-Day-Presentation_1245pm_v2.pdf, slides 12-24).